Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
3
3
0
0
MILLENDO THERAPEUTICSCS INC
Share · US60040X1037 · MLND · A2PAUC (XNCM)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of MILLENDO THERAPEUTICSCS INC
Analyst Grade Summary
No Price
Share Float & Liquidity
Free Float 76,20 %
Shares Float 8,01 M
Shares Outstanding 10,52 M
Company Profile for MILLENDO THERAPEUTICSCS INC Share
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Company Data
Name MILLENDO THERAPEUTICSCS INC
Company Millendo Therapeutics, Inc.
Symbol MLND
Website
http://www.millendo.com
Primary Exchange 
NASDAQ CAPITAL MARKET
NASDAQ CAPITAL MARKET
WKN A2PAUC
ISIN US60040X1037
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Julia Owens
Market Capitalization 11 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 110 Miller Ave Ste 100, 48104 Ann Arbor
IPO Date 2012-10-04
Stock Splits
| Date | Split |
|---|---|
| 28.06.2021 | 1:15 |
| 10.12.2018 | 1:15 |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | MLND |
More Shares
Investors who hold MILLENDO THERAPEUTICSCS INC also have the following shares in their portfolio:
